Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253160 · ClinicalTrials.gov registry record · NA
An Evaluation of the Spectra Optia CMNC Collection Procedure
A NA study of Healthy Apheresis Donors and Mononuclear (MNC) Cell Donors, sponsored by Terumo BCT.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT02253160 is a NA study of Healthy Apheresis Donors and Mononuclear (MNC) Cell Donors that has completed, run by Terumo BCT. The registered enrollment target is 23 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02253160, a NA study of Healthy Apheresis Donors and Mononuclear (MNC) Cell Donors, has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this prospective, randomized, cross-over, multi-center study is to evaluate the performance of the Spectra Optia Apheresis System's CMNC Collection Procedure, compared to the COBE Spectra Apheresis System's MNC Procedure in mobilized healthy donors. Subject safety will be evaluated beginning with mobilization, throughout the collection procedure and for the day following the last collection.
Conditions Studied
Interventions
- DEVICE Spectra Optia CMNC
- DEVICE COBE Spectra MNC
- DRUG Granulocyte-colony stimulating factor (G-CSF)
Study Locations (2)
Ohio
- Hoxworth Blood Center - Cincinnati
Tennessee
- Key Biologics, LLC - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253160
The ClinicalTrials.gov registry entry for NCT02253160 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Terumo BCT, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Apheresis Donors appearing as the primary indexed condition, and to 3 interventions - of which Spectra Optia CMNC is the first listed.
NCT02253160 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02253160 about?
NCT02253160 is a clinical study titled "An Evaluation of the Spectra Optia CMNC Collection Procedure". The purpose of this prospective, randomized, cross-over, multi-center study is to evaluate the performance of the Spectra Optia Apheresis System's CMNC Collection Procedure, compared to the COBE Spectra Apheresis System's MNC Procedure in mobilized healthy donors. Subject safety will be evaluated be...
What is the current status of trial NCT02253160?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2014-09. Estimated completion is 2015-01.
What conditions does trial NCT02253160 study?
This clinical trial studies the following conditions: Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors.
What interventions are being tested in trial NCT02253160?
The interventions under investigation include: Spectra Optia CMNC (DEVICE), COBE Spectra MNC (DEVICE), Granulocyte-colony stimulating factor (G-CSF) (DRUG).
Who is sponsoring clinical trial NCT02253160?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02253160 being conducted?
This trial has 2 study locations across Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.